Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer

Amy H. Tien,Marianne D. Sadar

DOI: https://doi.org/10.3390/ijms25031817

IF: 5.6

2024-02-03

International Journal of Molecular Sciences

Abstract:Breast cancer is a major cause of death worldwide. The complexity of endocrine regulation in breast cancer may allow the cancer cells to escape from a particular treatment and result in resistant and aggressive disease. These breast cancers usually have fewer treatment options. Targeted therapies for cancer patients may offer fewer adverse side effects because of specificity compared to conventional chemotherapy. Signaling pathways of nuclear receptors, such as the estrogen receptor (ER), have been intensively studied and used as therapeutic targets. Recently, the role of the androgen receptor (AR) in breast cancer is gaining greater attention as a therapeutic target and as a prognostic biomarker. The expression of constitutively active truncated AR splice variants in breast cancer is a possible mechanism contributing to treatment resistance. Therefore, targeting both the full-length AR and AR variants, either through the activation or suppression of AR function, depending on the status of the ER, progesterone receptor, or human epidermal growth factor receptor 2, may provide additional treatment options. Studies targeting AR in combination with other treatment strategies are ongoing in clinical trials. The determination of the status of nuclear receptors to classify and identify patient subgroups will facilitate optimized and targeted combination therapies.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the role of androgen receptor (AR) and its splicing variants in the treatment of breast cancer. Specifically, the paper focuses on the following aspects:

1. **Expression of AR and its splicing variants in breast cancer**: The paper discusses the expression of AR and its splicing variants (especially AR - V7) in different types of breast cancer, as well as the relationship between these expressions and the prognosis of patients.

2. **Potential of AR as a treatment target**: The paper evaluates the application prospects of treatment methods targeting AR and its splicing variants in breast cancer, especially the potential value in triple - negative breast cancer (TNBC).

3. **Interaction between AR and other receptors**: The paper explores the interactions between AR and estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as the effects of these interactions on the proliferation of breast cancer cells and treatment response.

4. **Role of AR in different subtypes of breast cancer**: The paper analyzes the different roles of AR in ER - positive breast cancer and ER - negative breast cancer (including HER2 - positive and TNBC), including the possible tumor - suppressing and tumor - promoting effects of AR.

Through these studies, the paper aims to provide new strategies and ideas for personalized treatment of breast cancer, especially for patient groups for whom traditional treatment methods are not effective.